Author Information

ABOUT THE JOURNAL
• Informed consent and patient details
• Use of inclusive language
• Supplement Policy
• Supplement Proposals
• Initial Review
• Supplement Manuscripts
• Supplement Peer Review
• Disclosures/Conflicts of Interest
ORIGINALITY
• Submission declaration and verification
• Authorship
• Open access
• Ethics in publishing
• Human and animal rights




Informed consent and patient details

Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author but copies should not be provided to the journal. Only if specifically requested by the journal in exceptional circumstances (for example if a legal issue arises) the author must provide copies of the consents or evidence that such consents have been obtained. For more information, please review the Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals. Unless you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.

Use of inclusive language

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. When coding terminology is used, we recommend to avoid offensive or exclusionary terms such as "master", "slave", "blacklist" and "whitelist". We suggest using alternatives that are more appropriate and (self-) explanatory such as "primary", "secondary", "blocklist" and "allowlist". These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

Supplement Policy

Kidney International Supplements (KI Supplements) is a peer-reviewed companion journal to Kidney International. KI Supplements publishes articles on all aspects of renal research that may be of interest to the renal researcher and the practicing nephrologist. The format is sponsored, topical content of interest to the nephrology community. The journal is complimentary to subscribers of Kidney International.

Supplement Proposals

KI Supplements will consider publication of sponsored supplements that are of interest to its readers and demonstrate scientific validity. KI Supplements issues are a collection of previously unpublished articles on a common topic. The topic must be treated in an impartial, unbiased manner. There should be enough articles in the proposal to provide an unbiased and balanced view of the topic under discussion. No pharma-funded single article supplements will be considered (Society guidelines are an exception). Single articles from not-for-profit organizations will be evaluated depending on scope and nature of content. When published, content in the supplement should be current and not older than 12 months from development or from presentation at a conference. Publication costs must be borne entirely by the sponsor(s).

Submit your supplement proposals to:
Craig Smith
Advertising Sales Manager, Elsevier
230 Park Avenue, Suite 800
New York, NY 10169, USA
Email: [email protected]
Tel: (+1) 212-462-1933
Your proposal must include the following information:
  • Title and Scope of the Supplement (including proposed table of contents and authors, if available)
  • Name of the Sponsor/Funder
  • Origin of the content (Product of research, Clinical Trial, Meeting symposium, etc.)
  • Objective of the publication of the supplement
  • Expected submission date and/or publication date


Initial Review

The supplement proposal will initially be reviewed by the publishing team at Elsevier. If deemed suitable, it will be shared with the Editor-in-Chief of KI Supplements, who will review and determine if the project should be considered for publication. If it is decided to proceed, the assignment of a Guest Editor will be discussed between the Editor-in-Chief and Elsevier and proposed to the sponsor. Elsevier will provide a cost estimate and a publication schedule, including a manuscript submission deadline and an estimated month of publication. Please note that publication of specific content is not guaranteed until after materials are submitted in accordance with the deadline and undergo peer review and revision as necessary. If there are any delays in submitting final manuscripts or proofs, it may be necessary to delay publication.

Supplement Manuscripts

Supplement manuscripts must be prepared and submitted according to the Kidney International Guide for Authors. Manuscripts that do not follow these guidelines will be returned for editing before review, and the editorial office will not begin processing any supplement articles until all the manuscripts for the supplement are received.

Once the content of the supplement proposal is accepted by Elsevier and the Editor-in-Chief, the Guest Editor and the authors are invited to submit their editorial and articles on the ScholarOne website.

The manuscripts will be reviewed by the Editor-in-Chief, the Deputy Editor, or an Associate Editor.

Supplement Peer Review

Kidney International Supplements operates a single blind peer review process coordinated by the Editor-in-Chief or an Associate Editor. All supplement articles undergo review of their contents by at least one external peer reviewer. The Editor-in-Chief reserves the right to reject portions of the supplement or the entire supplement. The editorial office will contact the Guest Editor or Coordinator regarding the decision to accept, reject, or require revisions. Once a supplement has been accepted, it is formally scheduled for publication; changes to the publication date at this stage cannot be accommodated.

Disclosures/Conflicts of Interest

The supplement must include a statement indicating the source(s) of funding. All authors should disclose what, if any, financial relationship they have with the sponsor of the supplement, or the manufacturer of any products, or competing products, that are discussed in their manuscripts. Each manuscript must indicate any support that was obtained for the manuscript or its contents. If medical writer(s)/editor(s) have been involved, their role must be explicitly acknowledged, and their affiliation/source of funding must be listed. Additionally, if the sponsor has a financial interest in a product either directly or indirectly discussed in the manuscript, this relationship should be identified, along with the name of the product. Information about funding, sponsorship, and related products will be published with each article in the supplement and summarized in a frontmatter page in the supplement.

Publication of a supplement does not constitute product or sponsor endorsement by the International Society of Nephrology, Elsevier, or Kidney International Supplements, and a disclaimer indicating this will be printed in the supplement and published online.

Articles published in KI Supplements are subject to the same copyright restrictions that apply to articles published in regular journal issues of Kidney International.




Submission declaration and verification

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see https://www.elsevier.com/sharingpolicy), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. Permission for use within the submitted manuscript of any text, figures, tables, or data from other sources must be granted to the author, and must be on file prior to publication. If a modified, redrawn, or adapted figure is substantially similar to the original figure, permission from the original source is required. A simple color change or change of labels on an X and Y axis is not sufficient. Even in the rare circumstances where a figure has been modified, redrawn, or adapted enough so as not to require permission, the original source of the figure should nonetheless be acknowledged (e.g. ”Based on…“). When re-using a ”courtesy image“ from a non-Elsevier product, or from one Elsevier product in a different Elsevier product, permission must be obtained directly from the named individual or institution. To verify originality, your article may be checked by the originality detection service CrossCheck https://www.elsevier.com/editors/plagdetect.

Authorship

Requirements for all categories of articles should conform to the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals," developed by the ICMJE (http://www.icmje.org).

Each author must have contributed sufficiently to the intellectual content of the submission. The corresponding author should list all authors and their contributions to the work. The corresponding author must confirm that he or she has had full access to the data in the study and final responsibility for the decision to submit for publication. To qualify as a contributing author, one must meet all of the following criteria:
  1. Conceived and/or designed the work that led to the submission, acquired data, and/or played an important role in interpreting the results.
  2. Drafted or revised the manuscript.
  3. Approved the final version.
Contributions by individuals who made direct contributions to the work but do not meet all of the above criteria should be noted in the Acknowledgments section of the manuscript. Medical writers and industry employees can be contributors. Their roles, affiliations, and potential conflicts of interest should be included in the author list or noted in the Acknowledgments and/or Contributors section concurrent with their contribution to the work submitted. Signed statements from any medical writers or editors declaring that they have given permission to be named as an author, as a contributor, or in the Acknowledgments section is also required. Failure to acknowledge these contributors can be considered inappropriate, which conflicts with the journal's editorial policy.

Although the editors and referees make every effort to ensure the validity of published manuscripts, the final responsibility rests with the authors, not with Kidney International Supplements, its editors, the International Society of Nephrology, or Elsevier.

Open access

Please visit our Open Access page for more information.

Ethics in publishing

Please see our information on Ethics in publishing.

This journal is a member of, and subscribes to the principles of, the Committee on Publications Ethics (COPE) http://www.publicationethics.org.

Human and animal rights

If the work involves the use of animal or human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/; EU Directive 2010/63/EU for animal experiments http://ec.europa.eu/environment/chemicals/lab_animals/legislation_en.htm; Uniform Requirements for manuscripts submitted to Biomedical journals http://www.icmje.org, and in the case of renal transplant the Declaration of Istanbul (as published in KI Vol. 74 No. 7 [2008]). Kidney International Supplements will not consider manuscripts containing data derived from transplants obtained from executed prisoners. If authors wish to submit a manuscript related to this issue such as an editorial or review examining the consequences of such practices, they must contact the Editorial Office to obtain permission prior to submitting the manuscript. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.
Advertisement